GSK announces the FDA approval of daprodustat for the treatment of anemia due to chronic kidney disease (CKD) in adults on dialysis for at least four months.
Emma Walmsley says ambition to be pharma superpower at risk unless improvements made in key areas
Do GSK shares provide one of the FTSE 100's most reliable dividends right now? Full-year 2022 results show steady progress. The post Earnings: are GSK shares a buy after a big earnings rise? appeared first on The Motley Fool UK.